Antimicrobial resistance has during the last decades become a global public health problem. Metallo-β-lactamases (MBLs) which are broad-spectrum β-lactamases that inactivate virtually all β-lactams including carbapenems, are contributing to this health problem. In this study a novel MBL variant, termed VIM-26, identified in a Klebsiella pneumoniae isolate was studied. VIM-26 belongs to the VIM-family of MBLs and is a His224Leu variant of the well-characterized VIM-1 variant. In this study, we report the kinetic parameters, minimum inhibitory concentrations (MICs) and crystal structures of a recombinant VIM-26 protein, and compare them to previously published data on VIM-1, VIM-2 and VIM-7. The kinetic parameters and MIC determinations show that VIM-26, like VIM-7 has higher penicillinase activity, but lower cephalosporinase activity than VIM-1 and VIM-2. The four determined VIM-26 crystal structures revealed mono-and di-zinc forms, where the Zn1 ion has distorted tetrahedral coordination geometry with an additional water molecule (W2) at a distance of 2.6 to 3.7 Å, which could be important during catalysis. The R2 drug-binding site in VIM-26 is more open compared to VIM-2 and VIM-7, and neutrally charged due to Leu224 but also because of Ser228. Thus, the VIM-26 drug-binding properties are different than in the VIM-2 (Tyr224/Arg228) and VIM-7 (His224/Arg228) structures, indicating a role of these residues in the substrate specificity.
Introduction
Antimicrobial resistance is not a new problem, but the increasing prevalence of antimicrobial resistance and multidrug-resistant bacteria has resulted in a growing public health problem [1] . In Gram-negative bacteria, the emergence and dissemination of acquired carbapenemases such as metallo-β-lactamases (MBLs) are of particular concern [2, 3] . MBLs hydrolyzes and inactivates all β-lactams including carbapenems with the exception of monobactams. The genes encoding MBLs are frequently located in mobile genetic structures facilitating dissemination and spread among Gramnegative bacteria [3] . Further, bacterial isolates harboring MBLs are often co-resistant to other antimicrobial agents such as aminoglycosides, thus limiting treatment options [3, 4] .
The Verona integron-encoded metallo-β-lactamase (VIM) family currently includes >40 different VIM genes (http://www.lahey.org/Studies/) divided in the VIM-1, VIM-2 and VIM-7 subgroups [5] . was first reported in a clinical Klebsiella pneumoniae isolate from 2006 [6] . The isolate was found to be resistant to all β-lactams as well as aminoglycosides and ciprofloxacin and only susceptible to tigecycline and colistin [6] . VIM-26 differs from the well characterized VIM-1 by only one amino acid residue, a histidine to leucine substitution in position 224, and belongs to the VIM-1 subgroup. The amino acid sequence identity between VIM-26 and VIM-2 is 91%. Residue 224 is part of the loop including residues 223 to 240 named the L3 loop [7] , L10 loop [8] or L2 loop [9, 10] , and will herein be denoted the L3 loop. Mutagenesis studies of VIM-13 mutating Leu224 and Arg228 to His and Ser, respectively, as found in VIM-1, resulted in increased catalytic efficiency and elevated MIC values more similar to VIM-1, indicating the importance of the L3 loop [7] . In another study on VIM-23, which has just one amino acid difference compared to VIM-2, namely a serine at position 228 instead of an arginine as in VIM-2, a significant effect on MIC values in the same genetic background was observed with cephalosporins and ertapenem [11] . For other β-lactams the effect was similar between VIM-23 and VIM-2.
Residue 224 in the L3 loop, is a conserved lysine in many B1 family MBLs and found be critical for binding the carboxyl group on the C-3/C-4 atom of the substrate [2, 8, 12] . In the VIM family of enzymes residue 224 is found to be either a histidine such as in VIM-1, VIM-4, VIM-7 and VIM-31, a tyrosine such as in VIM-2 or a leucine such as in VIM-5, VIM-13, VIM-26 and VIM-28. We previously proposed, based on analysis of the crystal structure and docking experiments, that the His224 in VIM-7 was a residue determinant partly responsible for the poor affinity to positively charged cephalosporins [9, 13] . This was explained by the presence of a more positively charged R2 binding pocket repelling a positively charged substrate. In addition there are two stabilizing hydrogen bonds in VIM-2 involving Tyr224 [9] . We later confirmed this through structural and kinetic studies of a His224Tyr mutation of VIM-7 where we could show that the mutant was more active against positively charged cephalosporins compared to the wild type VIM-7 [14] . In a VIM-2 thiol based inhibitor complex it was found that both Arg228 and Asn233 are important for inhibitor binding and recognition [15] . The L3 loop of VIM-4 and VIM-7 include His224 and Arg228 in both enzymes [9, 16] , where His224 has a similar conformation in both enzymes. Arg228, however, points towards Zn2 in VIM-4, but has a more open conformation in VIM-7. Residue 228 is Ser in VIM-26 and VIM-1, but Arg in VIM-2, VIM-4, VIM-7 and VIM-31. All these finding underline the importance of residue 224 for the enzymatic activity and substrate specificity for this family of MBLs. Another loop important for the substrate specificity is the L1 loop (residues 60-66) situated opposite to the L3 loop, for example as shown for GIM-1 [10] .
To characterize VIM-26 and explore the influence of the residue composition of the L3 loop on activity, we made a recombinant version the enzyme and subsequently performed enzyme kinetics studies, microbiological testing and determined four three-dimensional structures based on crystallization of recombinant VIM-26.
Results and discussion
The VIM-family of MBLs is along with the New Delhi Metallo-β-lactamase (NDM) family the most prevalent and widespread MBLs globally [3, 17] . Inhibition of serine-β-lactamases has previously been used successfully to extend the life-time of β-lactam antibiotics [18] . Despite promising scientific results [19] , there is currently no clinically available inhibitor for MBLs [20] . Consequently, studies into the biochemical and structural characteristics of MBLs are important for future inhibitor design. In this study we have investigated the characteristics of VIM-26, a member of the VIM-MBLfamily [6] , in order to better understand the role of residue position 224 and particularly the L3 loop in substrate specificity.
Enzymatic characterization and MIC determinations
The steady state kinetic constants and MIC determinations for VIM-26 and the comparator enzymes (VIM-1, VIM-2 and VIM-7) are shown in Table 1 and Table 2 , respectively. The kinetic experiments showed that recombinant VIM-26 hydrolyzes penicillins more efficiently than cephalosporins and carbapenems (Table 1; Figure 1 ). Among the penicillins tested we found that VIM-26 hydrolyzed benzylpenicillin more efficiently than ampicillin (Table 1) . For the cephalosporins, VIM-26 was more efficient against cefuroxime compared to cefepime, ceftazidime and cefoxitin, mainly due to higher 5 | P a g e affinity (lower KM) but also higher turnover (higher kcat) for the former. The relative carbapenemase activity of VIM-26 was similar between imipenem and meropenem, but slightly lower towards ertapenem, mainly due to lower affinity. The kinetic properties of VIM-26 were generally also observed in the MIC determinations with only marginal increases in the MIC to cefoxitin and ertapenem ( Table 2 ).
Compared to the other VIM-variants, the overall trend was that VIM-26 and periplasmic purified VIM-7 [14] were more efficient penicillinases than VIM-1 [21] and VIM-2 [22] (Table 1 ). In contrast both VIM-1 (all cephalosporins) and to a certain degree VIM-2 (ceftazidime and cefoxitin) were more efficient cephalosporinases than VIM-26 and VIM-7. This was also in general reflected in the MIC values for most substrates ( Table 2 ) except for some discrepancies (e.g. VIM-2 and ceftazidime).
Kinetic analysis of VIM-5 [23] and VIM-13 [7] which along with VIM-26 also possesses Leu224 showed lower cephalosporinase activity compared to VIM-1 and VIM-2. This suggests that Leu224 could be involved in the lower cephalosporinase activity of VIM-26 as observed for other VIM-variants with Leu224. The catalytic efficiencies against the different carbapenems were found to be slightly lower for VIM-26 compared to VIM-1, VIM-2 and VIM-7. Generally, this could be attributed to lower binding affinities for these substrates since the turnover (kcat) for VIM-26 against carbapenems were in many cases higher than for VIM-1, VIM-2 and VIM-7. It should be noted that the comparison of the kinetic properties of VIM-26 to other different VIM-variants were done using previously determined data from different laboratories. This could obviously influence the results. However, previous experience with VIM-2 revealed no major discrepancies with previously published values when tested under different experimental conditions (Samuelsen et al., 2008 [13] ). Although the different VIM-genes were cloned into the same vector and E. coli background, the MIC values for some substrates did not correlate with the kinetic data. This could be due to several factors such as differences in enzyme expression, but could also indicate that in vitro determined properties do not always correlate to the in vivo setting.
The VIM-26 crystal structures
In order to gain further insight into the structure activity relationship of VIM-26, and to shed light on the role of Leu224 in the L3 loop, the crystal structure of the recombinant VIM-26 was solved ( Figure   2 ). (Table 5 ). Cys221 was oxidized into cysteinesulfonic residue in all VIM-26 structures (termed Osc221, Figure 3 ). Oxidation of Cys221 has also been observed in other subclass B1 MBLs (GIM-1, BcII, SPM-1) [10, 24, 25] , indicating that this cysteine is an oxidative sensitive residue. The oxidation is likely explained by lack of reducing agents during crystallization since addition of the reducing agent (e.g. TCEP and β-mercaptoethanol) resolved this issue for both the VIM-2 and VIM-7 crystal structures [9, 26] . Still radiation damage [27, 28] of Cys221 at the highly intense BL14.1 beamline at Bessy-II cannot be ruled out.
The VIM-26-PEG structure was obtained after a soak with the inhibitor D-captopril but the extra electron density in the active site was interpreted as a PEG molecule and not the inhibitor. The PEG molecule is protruding into the R1 binding site where Trp87 is found in two conformations, but the overall structure is similar to the three other VIM-26 structures.
Zinc binding in the metallo--lactamase VIM-26
The Zn1 found in the oxidised VIM-7 (PDB ID: 2Y8B) [9] . The role of residue 233 has been discussed as part of the substrate binding [29] [30] [31] [32] . This residue is found to be asparagine in the majority of the B1 MBLs [31] including VIM-26, but is a tyrosine in other MBLs, for example in GIM-1 [10] . The fifth Zn1 ligand was found in both mono (VIM-26-Mono) and the di-zinc (VIM-26-W) forms, reflecting flexibility in the enzyme. The geometry of all Zn1 sites was tetrahedral (Table 5B ) therefore the fifth Zn1 ligand could resemble a carbonyl oxygen of an incoming substrate [9, 33] . A fifth Zn1 ligand is infrequently reported, but could be important here since it interacts with the partly conserved Asn233 residue in the L3 loop [31] , the extra W2 water is adjacent the inhibitor bound to VIM-2 (PDB ID: 2YZ3; [15] ), it interacts with the hydrolytic hydroxyl ion in-between two zinc ions and since water molecules are used in the hydrolyses of substrates and thus must be replaced during catalysis.
The Zn2 ion was missing in the VIM-26-Mono structure as judged from the observed electron density, thus indicating a lower zinc affinity for the Zn2 binding site compared to the Zn1 site. For the three other VIM-26 structures the geometry and interatomic distances of the Zn2 ion are a distorted octahedron with the Zn2 ion in the center, His263 NE2 and W1/hydroxyl ion at the axial positions, and Asp120 OD2, Ocs221 OD2 and two water molecules (W3, W4) at the four equatorial positions.
The metal-to-metal distances are between 3.60 Å (VIM-26, VIM-26-W) to 3.86 Å (VIM-26-PEG; Table   5 ). The oxidised Cys221 has probably caused the reduced Zn2 occupancy (0.5 in VIM-26, 0.5 in VIM-26-W; 0.3 in VIM-26-PEG). Overall, the four presented structures shed light on the structural variation, flexible architecture and different coordination geometry of the metal centers in VIM-26.
Despite the overall good quality electron density maps in the determined VIM-26 structures, we cannot completely rule out that the oxidised Cys221 disturbs its local environment.
The L1 loop
The main chain conformations of the L1 loop in the four VIM-26 structures were similar, but in VIM-26-Mono, the Gln59, Tyr67, His263, Trp87 and Asp119 residues were slightly shifted compared to the other structures. In the VIM-26-PEG structure, Trp87 was found in two different conformations. In the VIM-26-Mono structure Trp87 was slightly shifted and made a polar interaction with Asp119 OD2 (Figure 2c ), whereas the Gln59 side chain was involved in a hydrogen bound to both Ala86 O (2.89 Å from NE2) and to Asn91 ND2 (3.11 Å from OE1). In the three other VIM-26 structures Gln59 NE2 was hydrogen bound to Trp87 O and the Gln59 side chain was water exposed. Tyr67 in the L1 loop of VIM-26-Mono was clearly rotated towards Trp87, although the OH-atoms were not defined in the observed electron density maps. Residue 87 is a tryptophan in all VIM crystal structures, found in one main rotamer conformation (VIM-2, VIM-4, VIM-7 [9, 15, 16, 26] and VIM-31 (PDB ID 4FSB, 4FR7)), except in oxidised VIM-31 (PDB ID: 4FSB). For VIM-26 it is also one preferable Trp87 conformation, and the one in VIM-26-Mono (Figure 2c ) is less frequent and influenced by the adjacent residues. The movements of residues Gln59, Tyr67, His263, Trp87 and Asp119 in VIM-26-Mono could be also linked to the missing Zn2 ion, since the crystal packing, unit cell and space group were similar for all four structures.
Implication of Leu224 in the L3 loop
VIM-26 differs from VIM-1 by a single residue, namely histidine 224 which has been substituted with a leucine [6] . This residue is part of the L3 loop involved in the R2 substrate binding site, and plays an important role in catalysis [2, 7, 14] . All the VIM-26 structures showed an open binding site for the R2 part of the substrates (Figure 4a) . We found that the electrostatic surface around the active site of VIM-26 showed a more neutral R2 site compared to VIM-2 and VIM-7 (Figure 4a, b, c) , and also compared to VIM-4 (data not shown). According to our analysis of the structure, the substitution of histidine to leucine at position 224 is mainly responsible for the neutral R2 site in VIM-26, but Ser228 also contributes to generate a larger pocket. In both VIM-2 and VIM-7, residue 228 is arginine contributing to a narrower pocket. In two VIM-2 crystal structures, one apo-structure and one inhibitor bound (PDB ID: 1KO3 and 2YZ3, respectively) as well as in a VIM-7 structure (PDB ID: 2Y87), Arg228 are found in very different conformations [9, 15] . The mutation of His224 in VIM-7 into Tyr, to resemble the sequence of VIM-2, increased the thermal stability and enzyme activity of the mutant [14] . Furthermore, the enzymatic activity increased compared to wild type particularly towards the positively charged cephalosporins cefepime and ceftazidime [14] , again underlining the 
Conclusion
The enzymatic characterization and MIC determinations showed that VIM-26, like VIM-7 is characterized with being a more efficient penicillinase than VIM-1 and VIM-2, but with lower 
MATERIALS AND METHODS

Cloning of blaVIM-26 from Klebsiella pneumonia isolate U-60687
The blaVIM-26 gene from a clinical Klebsiella pneumoniae isolate U-60687 [6] , was amplified using the following primers VIM-26-NdeI: 5'-GGAATTCCATATGTTAAAAGTTATTAGTTTATTGG-3' and VIM-26-BamHI: 5'-CGCGGATCCCTACTCGGCGACTGAGCGATTTTTGTG-3' (NdeI and BamHI restriction sites are indicated as bold and underscored bases). The PCR product was purified from the agarose gel using the QIAquick Gel extraction kit (Qiagen), digested with NdeI (NEB) and BamHI (NEB), and ligated into the pET-26b expression vector (Novagen), generating the plasmid pET26b:VIM-26.
Expression and purification of VIM-26
VIM-26 was expressed and purified from the periplasm as previously described relying on the native leader sequence for transport [9, 13, 34] . In short, the pET26b:VIM-26 was transformed into E. coli BL21(DE3) (Novagen). Transformed bacteria were grown in Terrific Broth supplemented with 50 mg/L kanamycin (Sigma) at 37°C. Expression was induced at mid log phase by addition of 0.1 mM isopropyl-β-D-thiogalactopyranoside (Sigma). The cells were harvested by centrifugation (4500 rpm, 30 min at 4C) four hours after induction. Recombinant VIM-26 was purified from the periplasm followed by ion exchange chromatography on a Q-Sepharose HP column (GE Healthcare) and size exclusion chromatography on a Superdex 200 column (GE Healthcare). Buffer A (50 mM Tris pH 7.2, 100 μM ZnCl2) was used for binding during ionic exchange purification, and elution took place during a gradient of Buffer B (Buffer A plus 500 mM NaCl). Size exclusion was carried out in Buffer A.
Purified VIM-26 was concentrated by ultrafiltration (3 kDa Cut off, Amicon) to a final concentration of 16.5 mg/ml protein with >95% purity as judged from SDS-PAGE analysis and stored at 4C. The purified protein was subjected to MS-MS analysis for identification after purification.
Enzyme kinetics on VIM-26
The protein concentration of purified VIM-26 was determined from the absorbance at 280 nm using 
Minimum inhibitory concentration (MIC) determination
The bla genes encoding VIM-1, VIM-2, VIM-7 or VIM-26 were amplified using Phusion High-Fidelity PCR mastermix (NEB). The following primers were used for amplification: VIM-1 and VIM-26; VIM-1- 
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VIM-26 crystallization, data collection and structure determination
Crystallization trials for recombinant VIM-26 were performed using in-house made screening kits and a Phoenix RE nanolitre crystallization robot (Rigaku), setting up 300 nl protein (16.5 mg/mL) and 300 nl reservoir solution by the sitting drop method in 96-well MRC 2 plates containing 60 μl reservoir.
Optimization was done using 24 well pre-greased plates Å. All data were integrated and scaled with XDS and XSCALE [36] .
The phase problem of VIM-26 was solved by the molecular replacement method using the program PHASER [37] and the VIM-7 X-ray structure (PDB ID: 2Y8B) [9] as a search model. From the molecular replacement search in the space group P21 only one solution with one molecule in the asymmetric unit was found. The models were refined in Phenix [38] and manually built in WinCoot [39] .
Docking of ceftazidime into VIM-26 was done using the six reported substrate conformations for hydrolyzed ceftazidime that was thoroughly docked into VIM-7 and VIM-2 [9] and fitting these conformations into the new VIM-26 structures. In brief, the hydrolyzed ceftazidime was fitted into VIM-26, treating the enzyme as a rigid receptor. The aim was to obtain interactions from the carboxylate group on the C8 atom of ceftazidime to the Zn1 ion and from the anionic nitrogen (N5) of β-lactam to Zn2, which is similar to the crystal structure complex of L1 MBL with the hydrolysis product of moxalactam [40] .
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